Background/Purpose Psoriasis continues to be a debilitating skin disease affecting 1-3% of the United States population. Although the effectiveness of several current biologic therapies have described this pathology as a IL-23, TNF-a and Th17-mediated disease, less invasive approaches are still in use and in need of refinement. One of these is the usage of narrow band-UVB (NB-UVB) therapy to deplete specifically intra-epidermal CD3+, CD4+ and CD8+ cells to clear psoriatic plaques.
SUMMARY
Background/Purpose Psoriasis continues to be a debilitating skin disease affecting 1-3% of the United States population. Although the effectiveness of several current biologic therapies have described this pathology as a IL-23, TNF-a and Th17-mediated disease, less invasive approaches are still in use and in need of refinement. One of these is the usage of narrow band-UVB (NB-UVB) therapy to deplete specifically intra-epidermal CD3+, CD4+ and CD8+ cells to clear psoriatic plaques.
Aims/Objectives
In order to improve NB-UVB therapy, we sought to determine whether skin pre-treatment with the TLR7 agonist imiquimod (IMQ) would help increase the efficiency of the former at resolving psoriatic plaques.
Materials and Methods

Eucerin
â Original Moisturizing Lotion (topical vehicle) or Aldara â (imiquimod 5% topical cream) were applied for 5 days once daily to a maximum contiguous area of 25 cm 2 (5 cm 9 5 cm area). Patients were provided with sachets containing 12.5 mg of imiquimod each and were instructed to apply imiquimod (I) to two psoriasis plaques (5 sachets of imiquimod allotted to each plaque). A PHAROS excimer Laser EX-308 (Ra Medical Systems, Inc. Carlsbad, CA, USA) with an output of monochromatic 308-nm light and pulse width of 20-50 ns was used for all patients. Punch biopsies of psoriatic lesions (6 mm) were taken at 4 and 48 h after final application of topical treatment with or without excimer laser treatment. Real-time quantitative RT-PCR was performed according to manufacturer's instructions and Inmunohistochemistry was used as described before.
Results
Our results suggests that although IMQ seemed to activate the type I interferon pathway as previously described, its concomitant usage with NB-UVB for clearing psoriatic skin was ineffective. Although upregulation of genes MxA, GRAMD1A and DMXL2 suggested that IMQ treatment did induce skin changes in psoriasis patients, more optimal dosing of IMQ and NB-UVB might be necessary to achieve desired treatment responses.
Conclusion
The observation that psoriasis involvement was not aggravated by usage of topical IMQ was encouraging. Additional observational studies might be necessary to further tailor the combination of IMQ with NB-UVB therapy to reliably improve the psoriatic pathology.
Photodermatol Photoimmunol Photomed 2017; 33: 193-202 The prevalence of psoriasis in the United States was 3.2% in patients older than 20 years from 2009 to 2010, according to the National Health and Nutrition Examination Survey (1). Psoriasis is a spectrum of clinical phenotypes, with plaque-type psoriasis as the most common form (2). Histologically, keratinocyte hyperproliferation and abnormal differentiation produce changes in the epidermis including elongation of the rete pegs, reduction or absence of the stratum granulosum, and retained nuclei or parakeratosis of stratum corneum keratinocytes, along with a mononuclear cell infiltrate in the dermis perivasculature and occasional collection of neutrophils (PMNs) in the stratum corneum (2). Pathogenic memory effector T cells expressing high CD2 and CD25 as activation markers are critical for psoriasis lesion maintenance, because LFA-3/CD2 heterodimer (Alefacept), and diptheria toxin-IL-2 (Diftotoxin) fusion protein both highly specific for activated T cells, result in clinical improvement (3) . Initially, T-helper (Th)-1 cells producing cytokines such as IFN-c and TNF-a were implicated in psoriasis pathogenesis based on increased expression of IL-12 and TNF in psoriatic plaques, and clinical responses to TNF inhibitors and anti-IL12 p40 (4) . However, the identification of cytokine IL-23, which consists of an IL-12 p40 subunit and p19 protein pair, and subsequent demonstration of the efficacy of anti-IL17A/F, anti-IL17R, and anti-IL23 led to the current concept that psoriasis is mainly an IL-23 and TNF-Th17-mediated disease.
Close to a century ago, ultraviolet B (UVB) therapy in combination with crude coal tar (Goeckerman therapy) was first reported to be effective for the treatment of psoriasis (5) . Subsequently, UVB as monotherapy, particularly in the narrow band spectrum of 311-312 nm, was found to be more effective and safe compared to a broader UVB spectrum (6) . In a bilateral comparison study, psoriatic plaques in 23 patients were treated daily with narrow band UVB (NB-UVB) (312 nm) or broad band UVB (BB-UVB). Although both treatment modalities decreased the amount of intra-epidermal T cells and dermal T cells (to a lesser extent) from psoriatic skin, there was more quantitative reduction with NB-UVB. Likewise, flow cytometry demonstrated a rapid reduction of CD3 + , CD4 + , and CD8 + T cells in the first 2 weeks of phototherapy of psoriatic epidermis (7) . Both in vitro and in vivo studies of psoriatic epidermis demonstrated apoptosis as the mechanism for T-cell reduction after phototherapy. The excimer laser, which delivers a 308-nm UVB radiation, is used to treat psoriasis. Among 15 patients with plaque psoriasis, the excimer laser was effective in clearing the skin (>95%) after a mean of 10.6 treatments with a mean cumulative dose per plaque of 6.1 J/cm 2 (range of 1.9-18.3 J/cm 2 ) (8) . The therapeutic mechanism of the excimer laser has been proposed to be apoptosis induction of lesional T cells in the epidermis and dermis, whether given in multiple doses, or as a single dose, (9, 10) .
The Toll-like receptor (TLR) 7 agonist imiquimod [1-(2-methylpropyl)-1H-imidazole(4,5-c)quinolin-4 amine] is an immune response modifier with efficacious antiviral and antitumor activities resulting from induction of interferon alpha (IFN-a) and other cytokines, stimulating both the innate and acquired host immunity (11) . The mechanisms by which topical imiquimod led to superficial basal cell carcinoma clearance was studied in six patients (12, 13) . After treatment with 5% imiquimod cream, basal cell carcinoma cells became more susceptible to apoptosis as demonstrated by decreased Bcl-2 expression immunohistologically. It was unclear if this was from direct imiquimod effect on the basal cell carcinoma or from indirect effects of imiquimod-induced local immunomodulation. Gene chip analysis of biopsies from these six patients revealed direct upregulation of the IFN-induced proteins including myxovirus resistance proteins (MxA and MxB) by IFN-a. In another study, the expression of MxA was analyzed in skin biopsies from patients with different cutaneous malignancies treated with imiquimod (14) . After imiquimod treatment, strong expression of MxA was demonstrated along with a Th-1 cellular immune response as evidenced by a robust lesional T-lymphocytic infiltration and expression of the chemokine receptor CXCR3. Therefore, MxA may be a surrogate marker of type 1 IFN signaling in skin treated with imiquimod.
Imiquimod has an immunomodulatory effects on psoriasis. In 3 case reports, pre-existing psoriasis was exacerbated clinically in patients with basal cell carcinoma or actinic keratoses treated with imiquimod (15) (16) (17) . Worsening of psoriasis histology was reported in a patient treated with imiquimod in conjunction with marked elevation of type I interferon and infiltration of plasmacytoid dendritic cells (18) . In another study using murine models, the pathogenesis of psoriasis induced by treatment with imiquimod was mediated by the IL-23/IL-17 axis (19) . Numerous subsequent reports have used imiquimod treatment as a surrogate for psoriasiform changes in murine skin (20) .
Based on the above mentioned existing knowledge and publications, we hypothesized that pretreatment of psoriasis lesions with imiquimod would activate the type I interferon signaling cascade from activation of lesional T cells. Because activated T cells are more susceptible to UVB apoptosis, we also hypothesized that laser UVB treatment of psoriasis lesions in such an activated state would result in enhanced lesion clearing at the site of UVB dosing.
MATERIALS AND METHODS
Patients
Seven patients of 14 screened who were at least 18 years old, with plaque-type psoriasis, were eligible and enrolled in the pilot study. Patients were recruited from the dermatology clinics of the University Hospitals Cleveland Medical Center in Cleveland, Ohio, USA, after informed consent was obtained to participate in an institutional review board approved protocol with ClinicalTrials.gov identifier, NCT00470392. Patients were instructed to discontinue any topical therapy at least one week prior to the study and any systemic therapy at least four weeks prior to the study. Patients were excluded if they had photosensitivity disorders; active untreated diseases or medication usage which may interfere with UVB, wound healing, or immune function; hypersensitivity to local anesthetic; inability to provide informed consent; and pregnant or lactating. A single dose of the excimer laser was administered to patients after imiquimod application followed by analyses of skin biopsies. Table 1 summarizes demographics of seven patients enrolled into the study.
Pretreatment with topical vehicle or imiquimod
Study patients served as their own control. Three morphologically and anatomically matched psoriasis plaque target lesions were identified and mapped on each patient (Fig. 1 ). Eucerin â (Beiersdorf Inc., Wilton, CT, USA)
Original Moisturizing Lotion (topical vehicle) or Aldara â (3M Corporation, St. Paul, MN, USA) (imiquimod 5% topical cream) were applied for 5 days (to mimic the regimen used to elicit inflammation in murine skin and to minimize any potential adverse events in this pilot study to allow completion of the treatments), once daily to a Fig. 1 . Study schematic diagram. Each oblong figure represent treated psoriasis plaques. h, hour/s; T, excimer 308-nm laser; V or I, vehicle (V) or imiquimod (I) applied daily for 5 days followed by skin biopsy; V + T or I + T, V or I applied daily for 5 days followed by excimer 308-nm laser treatment then biopsy at one 1 h postlaser treatment; I + 48 h, imiquimod applied daily for 5 days followed by skin biopsy 48 h after last dose; I + 48 h + T, imiquimod applied daily for 5 days followed by excimer 308-nm laser treatment 47 h after last dose then biopsy 1 h later.
maximum contiguous area of 25 cm 2 (5 cm 9 5 cm area). Patients were provided with sachets containing 12.5 mg of imiquimod each and were instructed to apply imiquimod (I) to two psoriasis plaques (five sachets of imiquimod allotted to each plaque). An equivalent amount of vehicle (V) was applied to one psoriasis plaque.
UVB Administration and skin biopsies
A PHAROS excimer Laser EX-308 (Ra Medical Systems, Inc., Carlsbad, CA, USA) with an output of monochromatic 308-nm light and pulse width of 20-50 ns was used for all patients. A fiber optic delivery system was connected to a handpiece, and the fluence was tuned to 3 mJ/cm 2 per pulse. A spot size of 3.2 cm of UV light was delivered to the patients. Half of one psoriatic plaque was exposed to excimer laser 4 h after final application of vehicle (V + T, A), whereas each half of two psoriasis plaques were exposed to excimer laser at 4 h (I + T, B) and 48 h (I + 48 h + T, C), respectively, after final application of imiquimod (Fig. 1a-c) . Prior to excimer laser treatment, each patient was evaluated for minimal erythema dose (MED) using the excimer laser based upon noninvolved skin; MED testing has been described in a previous paper (9) . The mean MED and excimer laser dose with ranges for study patients are reported in Table 1 . Punch biopsies of psoriatic lesions (6 mm) were taken at 4 and 48 h after final application of topical treatment with or without excimer laser treatment (Fig. 1) . We chose 4 and 48 h to capture 'acute' and 'chronic' points of treatment. Our reasoning was that although we were exposing patients to multiple imiquimod (IMQ) treatments, the IMQ-induced cellular response may activate T cells in a short time frame following exposure, thus 4 h following the final application of IMQ we exposed to UVB. Alternatively, we felt that we should also assess a condition where cellular response to IMQ treatment occurred at a slower rate, and thus, we irradiated at 48 h following the final IMQ treatment. Specimens were bisected; half was fixed in formalin, sectioned, and stained with hematoxylin and eosin (H&E), while the remaining half was frozen after embedding in an Optimal Cutting Temperature compound (TissueTek â ; O.C.T. compound, Sakura Finetek, CA, USA).
Evaluation of change in response to topical treatment (vehicle or imiquimod) only or topical treatment plus the 308-nm excimer laser Clinical responses were assessed by change from baseline using lesional Psoriasis Area and Severity Index (L-PASI) scores and photographs, 2 weeks after vehicle (V) or imiquimod (I) pretreatment with and without excimer laser irradiation. In our previous laser UVB study (Kagen et al. 9) , we examined patients at 2, 4 and 8 weeks post-UVB treatment. Based on the results of the previous study, the majority of response occurred by 4 weeks post-treatment. As we expected to accelerate the response with IMQ, we chose to examine patients at the 2 week time point. Histological responses, measures of apoptosis, cytokine responses, and mRNA responses were performed using skin punch biopsies obtained following treatment.
Real-time quantitative RT-PCR
Total RNA was extracted from frozen sections of either imiquimod-or vehicle-treated patients using an RNeasy mini kit (Qiagen Inc., Germantown, MD, USA Waltham, MA, USA). Each PCR was performed in triplicate, using the following conditions: 2 min at 50°C and 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. Fold change was determined using the 2 -DDCT method using 18S as the endogenous control.
Inmunohistochemistry
Tissue sections were cut and fixed as described previously (27) . Briefly, frozen sections 8lm thick were cut and placed in slides. Slides were then dried 15 min at RT followed by 10 min dip in cold acetone. After 5 min at RT, slides were rinsed in PBS and blocked overnight at 4°C with chicken serum. The next day, Jun D (1 : 25), TNF (1 : 16), or MxA (1 : 50) primary antibodies were applied during 3 h 45 min at RT. Slides were then rinsed in PBS and secondary chicken antirabbit AlexaFluor â 647-conjugated antibodies at 1 : 100
were applied during 60 min at RT. Slides were then rinsed and counter-stained with DAPI and WGA-FITC and mounted using Fluoromount-G (Southern biotech, AL, USA). Images were acquired with a 25X PlanNeofluoar, NA 0.8 Imm. Korr, Ph2 objective on a Zeiss LSM 510 META laser scanning confocal microscope (Carl Zeiss Microimaging, Jenna, Germany) located at the Neurosciences imaging Center at Case Western Reserve University, Cleveland, Ohio.
RESULTS
Pretreatment with imiquimod followed by the 308-nm excimer laser had no consistent clinical response or histological effects on target psoriasis plaques
Although some patients exhibited clinical improvement (4/7), others had stable disease or worsening 2 weeks after treatment, relative to baseline, as assessed by L-PASI scores and clinical photographs at the site of treatment (Table 2 , Fig. 2 ). Two patients with mild to moderate psoriasis histologically also improved with vehicle. Following treatment with imiquimod, we assessed inflammation and mitosis changes in mild vs. severe psoriatic lesions 5 days postapplication (I) or at 5 days, then 48 h after halting imiquimod treatment (I + 48H).
Patients with mild (moderate) psoriasis appear to have increased numbers of inflammatory cells in the dermis and increased mitotic epidermal keratinocytes compared to patients with more severe disease (Fig. 3) .
Adverse events
Adverse events experienced by study subjects and attributed to the study treatments were mainly skin reactions including vesicle formation or blistering, tenderness, or reported burning sensation as summarized in Table 3 . These skin-limited reactions did not result in patient withdrawal. Two patients had exacerbation of their psoriasis. The second exacerbation was attributed to use of bandage tape, whereas the cause of exacerbation in the first patient was not attributed to the study treatments (cause unknown). Number of patients out of 7 with ≥2 points worsening in L-PASI score relative to baseline 2 weeks after treatment
L-PASI, lesional psoriasis area severity index score.
*These two patients had mild and moderate psoriasis histologically and improved with V clinically but no further change with I or T. h, hour/s; T, excimer 308-nm laser; V or I, vehicle (V) or imiquimod (I) applied daily for 5 days followed by skin biopsy; V + T or I + T, V or I applied daily for 5 days followed by excimer 308-nm laser treatment then biopsy 1 h later; I + 48 h, imiquimod applied daily for 5 days followed by skin biopsy 48 h after last dose; I + 48 h + T, Imiquimod applied daily for 5 days followed by excimer 308-nm laser treatment 47 h after last dose then biopsy 1 h later; 
Vanin upregulation in treated psoriatic plaques
Vanin1 and vanin 3 gene expression, previously reported to be upregulated in psoriasis lesional tissue, were both upregulated in plaques treated with either vehicle only (v) or imiquimod (I) (n = 1) compared to normal tissue controls (21) (Fig. 4) .
Imiquimod pretreatment effects and induction of genes
Imiquimod treatment of psoriasis skin induced an IFNa gene signature by eliciting an increase in MxA as detected by qPCR in 2/5 psoriatic lesions (Fig. 5 ). There is a greater than threefold increase in MxA in I, imiquimod; T, excimer 308-nm laser; V, vehicle; V + T, V applied daily for 5 days followed by excimer 308-nm laser treatment then biopsy 1 h later.
imiquimod treated relative to vehicle control in 2/5 psoriasis patients (P10 and P13), whereas the other patients with psoriasis did not upregulate MxA significantly. We sought to determine if TLR-7-associated signals were evident in patients with psoriasis following imiquimod treatment. As shown in Fig. 6 , TLR7 response genes are numerous but previous reports demonstrated that in patients with psoriasis TLR7 gene signatures were evident after treatment (22) . We therefore probed genes on the TLR7 regulation pathway including GRAMD1A, PTCHD1, and DMXL2.
The target gene was considered upregulated if there was a ≥1.5-fold increase in the mRNA expression. Upregulation of both GRAMD1A and DMXL2 genes was observed in one patient with elevated MxA, following imiquimod treatment, confirming that the gene response was specific to imiquimod treatment, as shown by the interaction diagram of TLR7 response genes [ Fig. 6 . Note DMLX2 and GRAMD1A]. The other patients examined did not exceed 1.5-fold increases in mRNA expression of any the TLR-7-specific target genes.
DISCUSSION
We hypothesized that treatment of psoriasis patients with the TLR7 agonist imiquimod (IMQ) would result in activation of cutaneous T cells, rendering them more susceptible to apoptosis induction by subsequent UVB exposure. Therefore, we performed an observational pilot study on seven patients with psoriasis whose involved plaques were exposed to either IMQ or vehicle control for 5 days, followed by exposure to a 308-nm excimer laser UVB source 4 h after the application of vehicle or IMQ and a plaque where UVB exposure was performed 48 h after treatment with IMQ. Biopsies were acquired from all treated plaques at 1 h following UV exposure.
Patient response to therapy was variable, as some patients with psoriasis exhibited clinical improvement, whereas others had stable disease or in the case of 2/7 patients, worsening of disease 2 weeks following treatment. At a histological level, response to IMQ treatment was also variable and appeared to be dependent upon the severity of the disease. Patients with milder disease (PASI 1-10) appeared to have a more dramatic histological response including increases in inflammatory cell infiltrate and increased numbers of epidermal mitotic keratinocytes compared to patients with moderate to severe disease (PASI ≥ 10). However, given the limited number of patients enrolled in this observational study, no statistically significant changes were evident.
We confirmed upregulated expression of gene targets previously reported to be upregulated in psoriatic tissue (21), and confirmed that expression of these target genes in psoriatic skin were not further induced following treatment with either vehicle or IMQ treatment, suggesting that further keratinocyte proliferation was not evident in these patients.
To confirm that IMQ treatment was occurring properly through TLR7 signaling pathways in psoriatic skin, we sought to determine whether the IFN-a regulated MxA gene pathway was activated in the IMQ-treated patients. We were able to isolate quality RNA from 5/7 skin biopsy samples obtained from patients with psoriasis for each treatment condition (Vehicle (V), Imiquimod (I), and Imiquimod 4 or 48 h (T) following application plus UV treatment and examined the levels of MxA expression in the tissue (23) . Induction (>1.5-fold) of MxA was observed in only 2/5 patients, whereas the other three patients had detectable levels of MxA in all treated conditions that did not increase significantly upon IMQ treatment. Immunohistochemical staining of MxA, JunD, and TNF-a did not reveal significant changes in protein expression following IMQ or vehicle treatment ( Figure S1 ).
The TLR7 gene pathway has numerous up-and down-stream genes associated with TLR7 (Fig. 6a) . Interestingly, several of these genes have been previously reported to be either down regulated or in some cases unchanged in patient skin with psoriasis that has responded to treatment as published previously (Fig. 6b) (22). We also probed target genes downstream from TLR7 including DMXL2 and GRAMD1A in our IMQtreated and IMQ-responsive patients (Fig. 6c) .
Adverse events associated with this study included skin blistering associated with UV exposure although this did not appear to be exacerbated by IMQ treatment. Although two patients reported exacerbation of their psoriasis, this was not due to IMQ treatment, as one patient reported exacerbation at the site of vehicle treatment and the other exacerbation was associated with irritation of the skin due to the adhesive bandage covering a biopsy site.
The lack of consistent histological change following IMQ or vehicle treatments may be primarily due to the short time period between the UV exposure and the biopsy, although the clinical changes were also quite variable. This suggests that a high level of interpersonal variation to IMQ treatment is likely or potentially that a higher dose of IMQ should be used to achieve more consistent clinical changes. The differential response between mild and moderate/severe psoriasis patient histological changes suggests that disease severity may be one of the factors affecting IMQ response.
Although no statistically different clinical responses were observed, IMQ treatment of patients with psoriasis did appear to stimulate the TLR7 pathway in 2/5 patients (24) . Given the reported exacerbation of psoriasis attributed to IMQ treatment (17, 18), we anticipated that adverse events associated with psoriasis worsening may have occurred, although this was not observed. Interestingly, a recent report in the BJD (25) reported that despite trying to induce psoriasis by IMQ treatment under occlusion (a more robust application method than we used), the authors did induce a psoriasis-like skin inflammation, although typical psoriasis did not develop, suggesting that induction of classic psoriasis may be more difficult than some case reports suggest. We also attempted to demonstrate that T-cell activation occurred following IMQ exposure; however, upregulation of T-cell death-associated genes, such as Tdag8 (26), was not observed (data not shown), suggesting again that the dose of IMQ may have been suboptimal, or that physical barriers such as skin penetration of IMQ limited the effect of the drug.
Limited positive outcomes (MxA response, GRAMD1A, and DMXL2 upregulation) suggest that IMQ treatment can induce skin changes in patients with psoriasis, but more optimal dosing of IMQ is necessary. The observation that psoriasis involvement was not aggravated by topical IMQ is encouraging; however, increasing dose and or administration frequency may alter these outcomes as well. It will be necessary in the future to perform additional observational studies to address these outstanding questions.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article: Figure S1 . Immunohistochemically, biopsies of psoriatic plaques treated with vehicle (V) or imiquimod (I or I + 48H) did not demonstrate significantly altered expression of either the T-cell activation protein Jun D (a) in one patient or imiquimod response proteins MxA in 2 patients (b and c) and TNF-a (d) in one patient.
